haematologic malignancies
Conditions
Interventions
A (Patients who underwent HSCT were retrospectively enrolled):NA
B (Patients who are scheduled for HSCT will be prospectively enrolled):NA
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
14 Years to 80 Years
Inclusion criteria
Inclusion criteria: Cohort A: 1) patients undergoing HSCT in West China Hospital from January 2015 to January 2024; 2) Clinical case information was relatively complete. Cohort B: 1) HSCT patients admitted to West China Hospital after February 2024; 2) agree to participate in the research project and sign the informed consent; 3) patients who are willing to accept regular follow-up.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS);Progression free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Engraftment time;Cumulative incidence of acute/chronic graft versus host disease ;Relapse rate;Non-relapse mortality (NRM);quality of life;state of nutrition;hemorrhagic cystitis;CMV reactivation and CMV disease;Infection;Other rare adverse events; | — |
Countries
China
Contacts
Public ContactTian Dong
West China Hospital, Sichuan University
Outcome results
None listed